Lampalizumab reduces geographic atrophy lesion progression

Monthly lampalizumab, a potential therapy for patients with geographic atrophy secondary to age-related macular degeneration, reduced lesion area progression by 20% compared to a sham control, according to results of the MAHALO study. The phase 2 clinical trial, a multicenter, randomized controlled study, included patients with geographic atrophy secondary to age-related macular degeneration randomized into three treatment groups: 42 patients receiving 10 mg intravitreal injections of lampalizumab every month, 41 patients receiving injections every other month and 40 patients in a sham control group.

Full Story →